ArticleFrontiers in pharmacology2020
Inhibiting Extracellular Vesicle Trafficking as Antiviral Approach to Corona Virus Disease 2019 Infection.
Article in Frontiers in pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Multiorgan Molecular Landscape of Severe COVID-19 Revealed by Consensus Gene Signatures and RAB8B Targeting.Journal of medical virology · 2026Article
- Cardiac tissue model of immune-induced dysfunction reveals the role of free mitochondrial DNA and the therapeutic effects of exosomes.Science advances · 2024Article
- Shedding Lights on the Extracellular Vesicles as Functional Mediator and Therapeutic Decoy for COVID-19.Life (Basel, Switzerland) · 2023Review
- Circulating Extracellular Vesicles Impair Mesenchymal Stromal Cell Differentiation Favoring Adipogenic Rather than Osteogenic Differentiation in Adolescents with Obesity.International journal of molecular sciences · 2022Article
- Antimicrobial Effects of Tetraspanins: A New Turnabout in Treatment of Microorganisms.The Malaysian journal of medical sciences : MJMS · 2022Review
- ACE2-enriched extracellular vesicles enhance infectivity of live SARS-CoV-2 virus.Journal of extracellular vesicles · 2022Article
- Anti-SARS-CoV-2 Activity of Extracellular Vesicle Inhibitors: Screening, Validation, and Combination with Remdesivir.Biomedicines · 2021Article
- Efficacy of mesenchymal stromal cells and cellular products in improvement of symptoms for COVID-19 and similar lung diseases.Biotechnology and bioengineering · 2021Review
- Dissecting lipid metabolism alterations in SARS-CoV-2.Progress in lipid research · 2021Review
- Diverse Effects of Exosomes on COVID-19: A Perspective of Progress From Transmission to Therapeutic Developments.Frontiers in immunology · 2021Review
- Endothelial Senescence and Chronic Fatigue Syndrome, a COVID-19 Based Hypothesis.Frontiers in cellular neuroscience · 2021Article
- Mechanistic and Therapeutic Implications of Extracellular Vesicles as a Potential Link Between Covid-19 and Cardiovascular Disease Manifestations.Frontiers in cell and developmental biology · 2021Article
- Extracellular Vesicles in Viral Infections: Two Sides of the Same Coin?Frontiers in cellular and infection microbiology · 2020Review
- Diagnostic and Therapeutic Potential of Extracellular Vesicles.Technology in cancer research & treatmentReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.